The molecular classification of cancer‐associated fibroblasts on a pan‐cancer single‐cell transcriptional atlas
Clinical and Translational Medicine · 2023-12 · 13 (12)
DOI: 10.1002/ctm2.1516 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, online erschienen am 26.12.2023. Verfasst von Bonan Chen und 28 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Sir Y.K. Pao Cancer Center, The Chinese University o…. Hauptthemen laut MEDLINE: Cancer-Associated Fibroblasts, Neoplasms. Die Arbeit wurde bisher 84-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China (NSFC), Comprehensive Precision Oncology Program at The Chinese University of Hong Kong (Kingboard PROCURE Program), Health and Medical Research Fund.
Abstract (Originalsprache)
Background
Cancer‐associated fibroblasts (CAFs), integral to the tumour microenvironment, are pivotal in cancer progression, exhibiting either pro‐tumourigenic or anti‐tumourigenic functions. Their inherent phenotypic and functional diversity allows for the subdivision of CAFs into various subpopulations. While several classification systems have been suggested for different cancer types, a unified molecular classification of CAFs on a single‐cell pan‐cancer scale has yet to be established.
Methods
We employed a comprehensive single‐cell transcriptomic atlas encompassing 12 solid tumour types. Our objective was to establish a novel molecular classification and to elucidate the evolutionary trajectories of CAFs. We investigated the functional profiles of each CAF subtype using Single‐Cell Regulatory Network Inference and Clustering and single‐cell gene set enrichment analysis. The clinical relevance of these subtypes was assessed through survival curve analysis. Concurrently, we employed multiplex immunofluorescence staining on tumour tissues to determine the dynamic changes of CAF subtypes across different tumour stages. Additionally, we identified the small molecule procyanidin C1 (PCC1) as a target for matrix‐producing CAF (matCAF) using molecular docking techniques and further validated these findings through in vitro and in vivo experiments.
Results
In our investigation of solid tumours, we identified four molecular clusters of CAFs: progenitor CAF (proCAF), inflammatory CAF (iCAF), myofibroblastic CAF (myCAF) and matCAF, each characterised by distinct molecular traits. This classification was consistently applicable across all nine studied solid tumour types. These CAF subtypes displayed unique evolutionary pathways, functional roles and clinical relevance in various solid tumours. Notably, the matCAF subtype was associated with poorer prognoses in several cancer types. The targeting of matCAF using the identified small molecule, PCC1, demonstrated promising antitumour activity.
Conclusions
Collectively, the various subtypes of CAFs, particularly matCAF, are crucial in the initiation and progression of cancer. Focusing therapeutic strategies on targeting matCAF in solid tumours holds significant potential for cancer treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Anatomical and Cellular Pathology, State Key Laboratory of Translational Oncology, Sir Y.K. Pao Cancer Center, The Chinese University of Hong Kong, Hong Kong, China.
- Institute of Digestive Disease, State Key Laboratory of Digestive Disease, Li Ka Shing Institute of Health Science, The Chinese University of Hong Kong, Hong Kong, China.
- CUHK-Shenzhen Research Institute, Shenzhen, China.
- School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou, China.
- Department of Pathology, Guangdong Province Key Laboratory of Molecular Tumor Pathology, Nanfang Hospital and Basic Medical College, Southern Medical University, Guangzhou, China.
- Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, China.
ORCID-Profile: Bonan Chen, Shihua Shi, Jun Yu, Wei Kang
Förderung
- National Natural Science Foundation of China (NSFC)
- Comprehensive Precision Oncology Program at The Chinese University of Hong Kong (Kingboard PROCURE Program)
- Health and Medical Research Fund
- CUHK Direct Research Grant
- Cheng Yue Pui Charity Foundation
Zitieren
APA
Chen, B., Chan, W. N., Xie, F., Mui, C. W., Liu, X., Cheung, A. H. K., Lung, R. W. M., Chow, C., Zhang, Z., Fang, C., Yu, P., Shi, S., Zhou, S., Chen, G., Wang, Z., Wang, S., Ding, X., Huang, B., Liang, L., …, & To, K. F. (2023). The molecular classification of cancer‐associated fibroblasts on a pan‐cancer single‐cell transcriptional atlas. Clinical and Translational Medicine, 13(12). https://doi.org/10.1002/ctm2.1516
Vancouver
Chen B, Chan WN, Xie F, Mui CW, Liu X, Cheung AHK, et al. The molecular classification of cancer‐associated fibroblasts on a pan‐cancer single‐cell transcriptional atlas. Clinical and Translational Medicine. 2023;13(12). doi:10.1002/ctm2.1516
BibTeX
@article{Chen2023,
author = {Chen, Bonan and Chan, Wai Nok and Xie, Fuda and Mui, Chun Wai and Liu, Xiaoli and Cheung, Alvin H K and Lung, Raymond W M and Chow, Chit and Zhang, Zhenhua and Fang, Canbin and Yu, Peiyao and Shi, Shihua and Zhou, Shikun and Chen, Guoming and Wang, Zhangding and Wang, Shouyu and Ding, Xiaofan and Huang, Bing and Liang, Li and Dong, Yujuan and Wong, Chi Chun and Wu, William K K and Cheng, Alfred S L and Wong, Nathalie and Yu, Jun and Lo, Kwok Wai and Tse, Gary M K and Kang, Wei and To, Ka Fai},
title = {The molecular classification of cancer‐associated fibroblasts on a pan‐cancer single‐cell transcriptional atlas},
journal = {Clinical and Translational Medicine},
year = {2023},
volume = {13},
number = {12},
doi = {10.1002/ctm2.1516}
}
EUVIMED